Mankind Pharma Ltd (MANKIND) - Net Assets

Latest as of March 2026: Rs165.61 Billion INR ≈ $1.79 Billion USD

Based on the latest financial reports, Mankind Pharma Ltd (MANKIND) has net assets worth Rs165.61 Billion INR (≈ $1.79 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs280.80 Billion ≈ $3.04 Billion USD) and total liabilities (Rs115.18 Billion ≈ $1.25 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See MANKIND net asset quality score to measure how much of total assets are equity-financed.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs165.61 Billion
% of Total Assets	58.98%
Annual Growth Rate	27.75%
5-Year Change	162.2%
10-Year Change	N/A
Growth Volatility	11.27

Mankind Pharma Ltd - Net Assets Trend (2019–2026)

This chart illustrates how Mankind Pharma Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Mankind Pharma Ltd market cap and net worth.

Annual Net Assets for Mankind Pharma Ltd (2019–2026)

The table below shows the annual net assets of Mankind Pharma Ltd from 2019 to 2026. Also explore Mankind Pharma Ltd annual equity growth to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2026-03-31	Rs165.61 Billion ≈ $1.79 Billion	+13.68%
2025-03-31	Rs145.68 Billion ≈ $1.58 Billion	+52.14%
2024-03-31	Rs95.76 Billion ≈ $1.04 Billion	+25.19%
2023-03-31	Rs76.49 Billion ≈ $827.19 Million	+21.10%
2022-03-31	Rs63.16 Billion ≈ $683.08 Million	+29.89%
2021-03-31	Rs48.63 Billion ≈ $525.90 Million	+32.45%
2020-03-31	Rs36.72 Billion ≈ $397.07 Million	+23.14%
2019-03-31	Rs29.82 Billion ≈ $322.46 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Mankind Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 278.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Retained Earnings	Rs138.04 Billion	84.69%
Common Stock	Rs412.80 Million	0.25%
Other Components	Rs24.55 Billion	15.06%
Total Equity	Rs163.00 Billion	100.00%

Mankind Pharma Ltd Competitors by Market Cap

The table below lists competitors of Mankind Pharma Ltd ranked by their market capitalization.

Company	Market Cap
China Pacific Insurance (Group) Co. Ltd F:75C	$10.19 Billion
Camden Property Trust NYSE:CPT	$10.19 Billion
Lupin Limited NSE:LUPIN	$10.20 Billion
BALOISE HLDG AG ADR/1/10 F:BLO	$10.20 Billion
Shenzhen Megmeet Electrical Co Ltd SHE:002851	$10.16 Billion
Shenzhen Fastprint Circuit Tech Co Ltd SHE:002436	$10.16 Billion
Wintrust Financial Corporation NASDAQ:WTFC	$10.14 Billion
Darling Ingredients Inc NYSE:DAR	$10.14 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mankind Pharma Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 143,323,900,000 to 163,003,400,000, a change of 19,679,500,000 (13.7%).
Net income of 19,129,300,000 contributed positively to equity growth.
Dividend payments of 412,700,000 reduced retained earnings.
New share issuances of 214,600,000 increased equity.
Other comprehensive income increased equity by 6,237,300,000.
Other factors decreased equity by 5,489,000,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs19.13 Billion	+11.74%
Dividends Paid	Rs412.70 Million	-0.25%
Share Issuances	Rs214.60 Million	+0.13%
Other Comprehensive Income	Rs6.24 Billion	+3.83%
Other Changes	Rs-5.49 Billion	-3.37%
Total Change	Rs-	13.73%

Book Value vs Market Value Analysis

This analysis compares Mankind Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.78x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 32.36x to 5.78x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2019-03-31	Rs70.47	Rs2280.50	x
2020-03-31	Rs87.00	Rs2280.50	x
2021-03-31	Rs117.88	Rs2280.50	x
2022-03-31	Rs153.65	Rs2280.50	x
2023-03-31	Rs185.61	Rs2280.50	x
2024-03-31	Rs233.40	Rs2280.50	x
2025-03-31	Rs354.18	Rs2280.50	x
2026-03-31	Rs394.36	Rs2280.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mankind Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 11.74%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.40%
• Asset Turnover: 0.51x
• Equity Multiplier: 1.72x
Recent ROE (11.74%) is below the historical average (20.43%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2019	20.49%	11.62%	1.21x	1.46x	Rs2.96 Billion
2020	29.56%	17.57%	1.16x	1.46x	Rs6.82 Billion
2021	26.80%	20.36%	0.98x	1.35x	Rs7.93 Billion
2022	23.29%	18.42%	0.85x	1.49x	Rs8.18 Billion
2023	17.24%	14.65%	0.90x	1.31x	Rs5.38 Billion
2024	20.43%	18.65%	0.86x	1.28x	Rs9.77 Billion
2025	13.89%	16.31%	0.44x	1.94x	Rs5.58 Billion
2026	11.74%	13.40%	0.51x	1.72x	Rs2.83 Billion

Industry Comparison

This section compares Mankind Pharma Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $28,018,515,021
Average return on equity (ROE) among peers: 13.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Mankind Pharma Ltd (MANKIND)	Rs165.61 Billion	20.49%	0.70x	$10.19 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$354.09 Million	3.07%	2.25x	$30.30 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.00 Billion	13.75%	2.66x	$420.83 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$13.86 Billion	-0.01%	0.47x	$773.91 Million
Abbott India Limited (ABBOTINDIA)	$3.05 Billion	19.95%	0.50x	$6.00 Billion
Ajanta Pharma Limited (AJANTPHARM)	$25.99 Billion	18.00%	0.28x	$4.74 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$33.31 Billion	7.66%	0.64x	$1.27 Billion
Alkem Laboratories Limited (ALKEM)	$12.05 Billion	19.50%	0.29x	$6.67 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$964.67 Million	9.99%	0.49x	$153.02 Million
Alembic Pharmaceuticals Limited (APLLTD)	$50.67 Billion	22.63%	0.32x	$1.75 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$138.92 Billion	17.02%	0.90x	$10.33 Billion

About Mankind Pharma Ltd

NSE:MANKIND India Drug Manufacturers - Specialty & Generic

Market Cap

$10.19 Billion

Rs941.95 Billion INR

Market Cap Rank

#2197 Global

#93 in India

Share Price

Rs2280.50

Change (1 day)

+0.02%

52-Week Range

Rs1927.40 - Rs2660.60

All Time High

Rs2998.40